This study involved four major activities in estimating the current size of the plasma fractionation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Expected Revenue Growth in Plasma Fractionation Market Size:
[278 Pages Report] The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
In 2019, the immunoglobins segment accounted for the largest share of the plasma fractionation market
Based on product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products. Immunoglobulins accounted for the largest share of the global plasma fractionation market Industry Analysis in 2019. The large share of this segment is primarily attributed to the rising prevalence of neurological and immunological diseases, increasing off-label indications of IVIg, and growing use of SCIg due to its ease of administration and reduced administration time.
The pulmonology segment is expected to grow at the highest CAGR during the forecast period
Based on application, the plasma fractionation market size is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely by the rising prevalence of alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease (copd).
North America was the largest regional market for plasma fractionation in 2019.
Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing use of immunoglobulins in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD.
Request Sample Report on Plasma Fractionation Market:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284
Key Players In Plasma Fractionation Market:
Key players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), and BPL (UK), Sanquin (Netherlands).
